Tag Archives: Senesco Technologies Inc.

Senesco Provides SNS01-T Update on Phase 1b/2a Multiple Myeloma Trial

BRIDGEWATER, N.J., Jun 04, 2012 (BUSINESS WIRE) — Senesco Technologies, Inc. (“Senesco” or the “Company”) (nyse mkt:SNT) reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology. Read […]

Continue Reading

Senesco Announces $2.0 Million Equity Financing

BRIDGEWATER, N.J.–(BUSINESS WIRE)–Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that it has entered into a securities purchase agreement to raise approximately $2.0 million in gross proceeds through the sale of 7,692,308 shares of its common stock. The investors, excluding officers and directors of Senesco or funds affiliated with such officers […]

Continue Reading

Senesco and Rahan Meristem (1998) LTD Enter Into New Agreement

Bridgewater, N.J. (January 5th, 2011) – Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that it has re-structured its research and development agreement with Rahan Meristem (1998) Ltd (“Rahan”) to reflect the priorities of both Companies. “I am very pleased with the scientific progress we have made in the collaboration and […]

Continue Reading

SNS01-T Demonstrates Synergy with Lenalidomide in Cancer Model Results at Biotech Showcase 2012 in San Francisco

BRIDGEWATER, N.J. (January 3rd, 2012) – Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that the combination of lenalidomide and SNS01-T, the subject of Senesco’s on-going multiple myeloma clinical study, performs better than either treatment alone in mouse xenograft models of human mantle cell lymphoma. The results will be presented with […]

Continue Reading

Senesco Receives Milestone Payment from Bayer CropScience

Bridgewater, N.J. (December 1st, 2011) – Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that Bayer CropScience has made an undisclosed R&D milestone payment related to Bayer’s use of Senesco’s technology in Brassica oilseeds (Canola oil). Senesco’s proprietary gene technology was licensed to Bayer CropScience in November 2006 to enhance Canola […]

Continue Reading

Senesco to Present at NYSSA’s 2011 Biotech / Specialty Pharma Conference Update on Recent Non-Clinical Efficacy Findings with SNS01-T

BRIDGEWATER, N.J. (November 22nd, 2011) – Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced that the Company will be presenting at NYSSA’s 2011 Biotech / Specialty Pharma Conference being held at The Conference Facilities of The New York Society of Security Analysts in New York City at 1540 Broadway, Suite 1010. Leslie […]

Continue Reading

Senesco Initiates Dosing in Phase 1b/2a Clinical Study of SNS01-T

First in Human Study of eIF5A Modulation in Treatment of Disease BRIDGEWATER, N.J.–(November 3, 2011)– Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today announced the initiation of patient dosing in its Phase 1b/2a clinical study of SNS01-T at the Mayo Clinic in Rochester, MN. The study is an open-label, multiple-dose, dose-escalation study […]

Continue Reading

Senesco Technologies to Present at BIO Investor Forum Conference

BRIDGEWATER, N.J.–(BUSINESS WIRE)– Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced that the Company will be presenting at the BIO Investor Forum conference on Tuesday, October 25th. Leslie J. Browne, Ph.D., President and CEO of Senesco will be presenting at 1:30 p. m. Pacific Time at the Palace Hotel in San Francisco, […]

Continue Reading

Senesco Finalizes Agreement with Mayo Clinic to Study SNS01-T in Multiple Myeloma

BRIDGEWATER, N.J.–(BUSINESS WIRE)– Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today announced that it has finalized a clinical trial agreement with Mayo Clinic in Rochester, MN to study SNS01-T, the Company’s lead therapeutic candidate for the treatment of multiple myeloma. Read more of this entry

Continue Reading
Follow

Get every new post delivered to your Inbox.

Join 85 other followers